ALCMI and Biocept Announce a Landmark Liquid Biopsy Clinical Trial

Posted by ALCF Staff on May 10th, 2017

The Addario Lung Cancer Medical Institute (ALCMI) and Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announce a clinical collaboration and initiation of the landmark ALCMI-009 liquid biopsy clinical trial, which was developed and will be conducted by ALCMI and its consortium of leading U.S. and international oncology centers. In this large-scale study, which plans to enroll 400 patients, Biocept’s Target Selector™ assay platform will be used to detect and assess cancer biomarkers found in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from the blood of patients with lung cancer.

Read the full press release here

Comments are closed.